Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hovon 172: Tasqforce; a Phase 1B/2 Trial with Tasquinimod in Patients with Myelofibrosis (Primary, Post-Pv or Post-Et) Refractory to or Intolerant for Jak2 Inhibition

Next Previous
Search
Trial Profile

Hovon 172: Tasqforce; a Phase 1B/2 Trial with Tasquinimod in Patients with Myelofibrosis (Primary, Post-Pv or Post-Et) Refractory to or Intolerant for Jak2 Inhibition

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tasquinimod (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Proof of concept
  • Acronyms Hovon 172

    • Most Recent Events

    • 16 Jun 2024 Trial design presented at the 29th Congress of the European Haematology Association
    • 22 Dec 2023 According to Active Biotech, Professor Rebekka Schneider-Kraman is the Principal Investigator of this trial.
    • 22 Dec 2023 According to Active Biotech, the start of the European study within the HOVON network, with full external funding by Oncode, which previously was planned to start in the latter part of Q1 2024, will not start until Q3 2024, due to administrative procedures of these multicenter trials in Germany and the Netherlands.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top